Your browser doesn't support javascript.
loading
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
Hemming, Matthew L; Bhola, Patrick; Loycano, Michael A; Anderson, Justin A; Taddei, Madeleine L; Doyle, Leona A; Lavrova, Elizaveta; Andersen, Jessica L; Klega, Kelly S; Benson, Morgan R; Crompton, Brian D; Raut, Chandrajit P; George, Suzanne; Letai, Anthony; Demetri, George D; Sicinska, Ewa.
Afiliación
  • Hemming ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Bhola P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Loycano MA; Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Anderson JA; Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Taddei ML; Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Doyle LA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lavrova E; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Andersen JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Klega KS; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Benson MR; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Crompton BD; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Raut CP; Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • George S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Demetri GD; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Sicinska E; Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res ; 28(11): 2397-2408, 2022 06 01.
Article en En | MEDLINE | ID: mdl-35325095
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Leiomiosarcoma Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Leiomiosarcoma Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article